Rheumatoid arthritis (RA) & Nanocurcumin: What real human research shows

By Dr Conor Kerley, PhD, nutrition researcher, and someone who lives with an autoimmune condition himself.

If you have rheumatoid arthritis you will already have been told about turmeric, probably by someone who has never had a swollen joint in their life. So here is the actual record. Curcumin, the active compound in turmeric, has now been tested in people with RA in around a dozen clinical trials and pooled in at least seven meta-analyses. Most of that research is positive. One large trial was not, and it is in here too. Nothing on this page is a reason to change or stop the medication your rheumatologist has prescribed.

Know someone who would find this useful?

Share this:

Quick answer

• Curcumin has been tested in people with rheumatoid arthritis since 2012. Trials report lower inflammation markers (CRP and ESR), fewer tender and swollen joints, and better disease-activity scores [1, 3, 4, 14].
• Meta-analyses that pool those trials come to the same conclusion, with the usual caveat that the trials are small and short [2, 9, 10, 14, 18, 20].
• The best results come from forms designed to be absorbed, including nanocurcumin, at doses far lower than plain turmeric [3, 4, 17].
• One well-run 52-week trial found curcumin did not help people stay in remission while their disease-modifying drugs were reduced [15]. It is a supplement, not a replacement for treatment.

Why curcumin is studied in RA at all

Rheumatoid arthritis is the immune system attacking the lining of the joints. The damage is driven by inflammatory signals, chiefly TNF-alpha, IL-6 and the NF-kB pathway, which is why the biologic drugs target exactly those. In the laboratory curcumin turns down the same signals, and it also shifts the balance between the immune cells that drive RA (Th17 cells) and the ones that calm it (regulatory T cells) [5]. That is the reason researchers started giving it to people with RA rather than just to cells in a dish.

What the human trials found

The first trial (2012)

The study most people quote is a pilot from 2012. Forty-five people with active RA were split three ways: curcumin on its own, the anti-inflammatory drug diclofenac on its own, or both together, for eight weeks. All three groups improved. The curcumin-only group had the biggest improvement in disease-activity score, and it was the only group with no drop-outs from side effects [1]. A pilot of 45 people is not proof of anything, but it was enough to get curcumin taken seriously in RA.

Trials with better-absorbed forms

Plain curcumin is very poorly absorbed, so the trials that followed mostly used forms built to get more of it into the body.

• A 2017 trial gave 36 people with RA a highly bioavailable curcumin at two doses (250 mg or 500 mg twice a day) or placebo for 90 days. Both curcumin groups improved on pain, ESR, CRP, rheumatoid factor and disease-activity score, and the improvements were larger at the higher dose [3].
• A 2019 trial used curcumin nanomicelle, a nano form, at 40 mg three times a day for 12 weeks [4]. Honest reading: joint counts and disease activity improved within the nanocurcumin group, but the difference against placebo did not reach significance. The authors called the changes "some positive changes... although not significant". A smaller dose than any plain-curcumin trial, and a smaller effect than the headlines suggest.
• Two trials in women with RA gave 500 mg of curcumin a day for eight weeks. The first reported improvements in CRP and in metabolic measures such as blood sugar and weight [6]. The second reported higher antioxidant capacity, lower oxidative stress and lower disease activity [16].
• A 2022 trial tested curcumin with and without strengthening exercises and reported that adding curcumin improved RA outcomes [12].
• A 2025 trial of a novel nano micelle curcumin in RA looked at immune markers rather than symptoms and reported a shift towards a less inflammatory immune profile [17].

The trial that found little

The largest and longest trial is the one to read carefully. In a 2023 phase III study, people with RA in remission had their disease-modifying drugs gradually withdrawn while taking either curcumin or placebo for 52 weeks. Two hundred people took part, on 1 g of curcumin with piperine twice a day or a placebo. After a year, 60% of the curcumin group were still flare-free, against 64% on placebo. No difference [15]. That is an important negative. Curcumin may help alongside treatment; the evidence does not support using it to come off treatment.

What the meta-analyses say

When researchers pool the RA trials together, the picture is consistent. Curcumin lowers CRP and ESR, the two blood markers of inflammation your rheumatologist checks, and improves disease-activity scores and joint counts compared with placebo [9, 14, 18, 20]. A 2022 review that pooled trials across ten autoimmune diseases concluded that curcumin and Curcuma longa extract "had good clinical efficacy in the treatment of Psoriasis, UC and RA" [11]. The recurring caveat, stated in almost every one of these reviews, is that the trials are small (most under 60 people) and short (8 to 12 weeks), so nobody yet knows about years of use.

The score so far

Why the form of curcumin matters

Turmeric powder is about 3% curcumin, and most of the curcumin you swallow passes straight through. That is why the early trials needed a gram or more a day, and why the more recent ones switched to forms engineered for absorption. The 2017 trial got its results with 500 mg to 1,000 mg a day of a bioavailable form [3]. The nanomicelle trials got theirs with around 120 mg a day [4, 17]. Note that those are nanocurcumin, not standard, plain curcumin. Results from one form do not automatically transfer to another, and the expert reviews make the same point when they warn that shop-bought curcumin products vary enormously in what they actually contain.

What about osteoarthritis?

Osteoarthritis is the wear-and-tear kind and far more common than RA. It has its own, larger body of curcumin research. A 2016 meta-analysis of eight trials, mostly in knee osteoarthritis, found that around 1,000 mg a day of curcumin reduced pain and improved function, with effects comparable to the painkillers used as comparators in some of the trials [2]. A 2022 meta-analysis covering both kinds of arthritis reached a similar conclusion [10]. So if the person who told you about turmeric has osteoarthritis rather than RA, they may well be right for their own joints.

Is it safe with methotrexate and biologics?

In the RA trials, curcumin was taken by people who stayed on their usual medication, including methotrexate and other disease-modifying drugs, and the reviews describe its safety profile as similar to placebo, with mild stomach upset the most common complaint [8, 9]. Two things to raise with your rheumatologist before starting: curcumin can add to the effect of blood thinners such as warfarin, and if you are on a drug that needs regular liver monitoring, tell the team you are taking it so they can read your bloods with that in mind. Do not reduce a prescribed drug because you have started curcumin. The 52-week trial is the clearest evidence there is on that point [15].

Frequently asked questions

What dose did the trials use?
Plain or standard curcumin: 500 mg to 1,500 mg a day. Bioavailable forms: 500 mg to 1,000 mg a day. Nanocurcumin: around 120 mg a day, taken as 40 mg three times.

How long before you would notice anything?
Most trials measured at eight or twelve weeks. The 2012 pilot reported changes at eight [1].

Does it lower the blood markers or just the pain?
Both. CRP and ESR fell in the trials and in the pooled analyses [9, 14, 18], which matters because those are objective measures rather than how sore you feel that day.

Can I take it instead of methotrexate?
No. The only long trial that tested curcumin while medication was withdrawn found it did not maintain remission [15].

Will turmeric in food do the same?
No trial in RA has used culinary turmeric. A teaspoon gives under 100 mg of poorly absorbed curcumin.

Where Gold Standard Curcumin fits in

The nanomicelle trials above used curcumin in a nano form at 40 mg per dose. If you are considering it, bring this article and the reference list to your next rheumatology appointment. It is written for your consultant as much as for you.

Related reading: Does curcumin help Crohn's or colitis? · Curcumin and psoriasis · Curcumin and autoimmune disease · Curcumin supplements, what the research shows

References

1. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719-1725. PMID 22407780.
2. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19(8):717-729. PMID 27533649.
3. Amalraj A, et al. A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled, two-dose, three-arm, and parallel-group study. J Med Food. 2017;20(10):1022-1030. PMID 28850308.
4. Javadi M, et al. Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: a randomized, double-blind, controlled trial. Int J Rheum Dis. 2019;22(10):1857-1862. PMID 31482684.
5. Mohammadian Haftcheshmeh S, Momtazi-Borojeni AA. Immunomodulatory therapeutic effects of curcumin in rheumatoid arthritis. Autoimmun Rev. 2020;19(8):102593. PMID 32540449.
6. Pourhabibi-Zarandi F, et al. Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2022;36(4):1797-1806. PMID 35178811.
7. Pourhabibi-Zarandi F, Shojaei-Zarghani S, Rafraf M. Curcumin and rheumatoid arthritis: a systematic review of literature. Int J Clin Pract. 2021;75(10):e14280. PMID 33914984.
8. Bagherniya M, et al. The clinical use of curcumin for the treatment of rheumatoid arthritis: a systematic review of clinical trials. Adv Exp Med Biol. 2021;1291:251-263. PMID 34331695.
9. Ebrahimzadeh A, et al. Effects of curcumin supplementation on inflammatory biomarkers in patients with rheumatoid arthritis and ulcerative colitis: a systematic review and meta-analysis. Complement Ther Med. 2021;61:102773. PMID 34478838.
10. Zeng L, et al. Efficacy and safety of curcumin and Curcuma longa extract in the treatment of arthritis: a systematic review and meta-analysis of randomized controlled trial. Front Immunol. 2022;13:891822. PMID 35935936.
11. Zeng L, et al. Curcumin and Curcuma longa extract in the treatment of 10 types of autoimmune diseases: a systematic review and meta-analysis of 31 randomized controlled trials. Front Immunol. 2022;13:896476. PMID 35979355.
12. Khan MK, Khan IA, Liaquat A. Therapeutic potential of curcumin with and without strengthening exercises in improving rheumatoid arthritis. J Coll Physicians Surg Pak. 2022;32(12):1640-1643. PMID 36474395.
13. Sotebeer M, White ND. Potential benefits of curcumin in rheumatoid arthritis. Am J Lifestyle Med. 2022;16(6):684-686. PMID 36389049.
14. Kou H, et al. Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1121655. PMID 37325651.
15. Bhat SS, et al. Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial. Rheumatol Int. 2023;43(12):2193-2200. PMID 37650921.
16. Pourhabibi-Zarandi F, et al. The efficacy of curcumin supplementation on serum total antioxidant capacity, malondialdehyde, and disease activity in women with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2024;38(7):3552-3563. PMID 38699839.
17. Khamar F, et al. Immunomodulatory effects of novel nano micelle based curcumin in rheumatoid arthritis patients: a double blind randomized clinical trial. Rheumatol Immunol Res. 2025;5(4):227-234. PMID 39802548.
18. Zhang F, Niu B. Effect of curcumin on inflammatory markers and disease activity in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2025;104(48):e46177. PMID 41327719.
19. Liu AJ, et al. Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials. Inflamm Res. 2025;75(1):2. PMID 41372521.
20. Fan Y, et al. Curcumin for the clinical treatment of rheumatoid arthritis: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Front Immunol. 2026;16:1726157. PMID 41601662.

---

Share this:

×